Liraglutide: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides →
📌TL;DR
- •4 community protocols documented
- •Evidence level: Structured Community Data
- •Based on 200 community reports
- •1 stacking patterns reported
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Daily vs. Weekly Injection | Liraglutide requires once-daily subcutaneous injection due to its 13-hour half-life. All clinical trials used daily dosing. | The daily injection requirement is seen as a significant disadvantage compared to weekly semaglutide or tirzepatide. Some community members specifically choose liraglutide because it allows more flexible day-to-day dose adjustment. | moderate Daily dosing creates higher injection burden but allows users to adjust doses more quickly based on tolerability and appetite. |
| Cost and Access | Clinical trials provided branded Saxenda free of charge. Retail cost exceeds $1,000/month without insurance. | Cost is a primary driver of community formulation choices. Compounded liraglutide and generic versions (since 2025) offer significantly lower costs. Many users switched to liraglutide specifically because compounded semaglutide became less available. | high Generic liraglutide (Teva, approved 2025) was approximately 30% cheaper than branded Saxenda, improving access. Liraglutide remains on the FDA shortage list, allowing continued compounding. |
| Relative Efficacy Expectations | SCALE trials showed 8.0% mean weight loss with liraglutide 3.0 mg vs 14.9% with semaglutide 2.4 mg (STEP 1). No direct head-to-head trial exists. | Community members generally view liraglutide as less effective for weight loss than semaglutide or tirzepatide. It is often described as a "starter" GLP-1 or a cost-effective alternative for those who cannot access the newer agents. | moderate While less potent than semaglutide for weight loss, liraglutide remains an effective FDA-approved option with a longer safety track record (approved 2014 for weight loss vs. 2021 for semaglutide). |
Compare these community approaches with published research findings.
Community Protocols
Standard Saxenda Weight Loss Protocol
Popular- Route
- Subcutaneous
- Dose
- 0.6-3.0 mg
- Frequency
- Once daily
- Duration
- Ongoing
FDA-approved escalation: 0.6 mg x1 week, 1.2 mg x1 week, 1.8 mg x1 week, 2.4 mg x1 week, then 3.0 mg maintenance daily
Compounded Liraglutide Protocol
Common- Route
- Subcutaneous
- Dose
- 0.6-3.0 mg
- Frequency
- Once daily
- Duration
- Ongoing
Uses compounded multi-dose vials; significantly cheaper than branded Saxenda; requires manual syringe measurement
Low-Dose Maintenance Protocol
Common- Route
- Subcutaneous
- Dose
- 1.2-1.8 mg
- Frequency
- Once daily
- Duration
- Ongoing
Some users find adequate appetite suppression at 1.2-1.8 mg daily and remain at sub-maximum doses to minimize side effects and reduce cost
Generic Liraglutide Protocol
Common- Route
- Subcutaneous
- Dose
- 0.6-3.0 mg
- Frequency
- Once daily
- Duration
- Ongoing
Since 2025, generic liraglutide (Teva) available at approximately 30% lower cost than Saxenda; same escalation schedule
Stacking Patterns
Liraglutide + Metformin Combination
CommonMany users combine prescribed liraglutide with metformin for enhanced glycemic control and modest additional weight loss; this is standard medical practice for T2D
Check stack compatibility and review potential side effects before combining peptides.
Unlock community dosing protocols and stacking combos
See the exact doses, routes, and schedules 200+ self-experimenters report. Free with email.
150+ peptide profiles · 30+ comparisons · 18 research tools
Sources
- Reddit r/Saxenda|Saxenda user experiences and dosing discussions(accessed 2026-02-16)
- Reddit r/Peptides|Liraglutide community protocol discussions(accessed 2026-02-16)
- Reddit r/Ozempic|Liraglutide vs semaglutide switching discussions(accessed 2026-02-16)
- OVYVO Medical Weight Loss|Compounded Liraglutide overview and dosing information(accessed 2026-02-16)
- Join Found|Compounded Liraglutide - Weight Loss, Benefits & How to Use(accessed 2026-02-16)
- Oreate AI (Reddit compilation)|Navigating the Affordable GLP-1 Landscape - Insights From Reddit(accessed 2026-02-16)
Community Evidence Overview#
This page presents aggregated community protocols and anecdotal reports for Liraglutide (Victoza/Saxenda). The information below is gathered from Reddit communities (r/Saxenda, r/Peptides, r/Ozempic), telehealth platforms, and user reports. This is not clinical evidence and should not be used as medical guidance.
Liraglutide has an established community following, though it is smaller than the semaglutide and tirzepatide communities. Interest in liraglutide has experienced a resurgence since 2025 with the availability of generic formulations and the restriction of compounded semaglutide.
Community Context#
Position Among GLP-1 Agonists#
In community discussions, liraglutide is often positioned as a more accessible entry point to GLP-1 therapy. With semaglutide and tirzepatide compounding restricted by FDA shortage resolutions, many community members have turned to liraglutide as an alternative that remains available through compounding pharmacies (since it is still on the FDA shortage list) and now through generic versions.
Generic Availability#
The approval of generic liraglutide (Teva Pharmaceuticals) in 2025 was a significant event in the community. As the first generic GLP-1 receptor agonist approved for weight loss, it improved access for cost-sensitive users. Community discussions frequently compare the cost-effectiveness of generic liraglutide versus compounded semaglutide versus branded options.
Commonly Reported Outcomes#
- Weight loss: Most users report 5-10% body weight reduction, consistent with clinical trial data
- Appetite suppression: Reported as noticeable but less dramatic than semaglutide or tirzepatide
- GI side effects: Nausea is the most commonly reported side effect, typically during the first 2-4 weeks of use
- Injection site reactions: Occasional reports of redness or discomfort at injection sites
- Transition patterns: Many users describe starting on liraglutide and later switching to semaglutide or tirzepatide for greater efficacy
Important Caveats#
- Liraglutide is an FDA-approved prescription medication and should be used under medical supervision
- Compounded liraglutide is not FDA-approved and may vary in quality
- Community experiences with liraglutide generally show less dramatic weight loss compared to semaglutide or tirzepatide
- Individual results vary based on dose, diet, exercise, and adherence
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles · 30+ comparisons · 18 research tools
Frequently Asked Questions About Liraglutide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.